Product Description: Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer[1][2][3].
Applications: Neuroscience-Neuromodulation
Formula: C18H26ClN3O3
References: [1]Chen M, et al. Prucalopride inhibits lung cancer cell proliferation, invasion, and migration through blocking of the PI3K/AKT/mTor signaling pathway. Hum Exp Toxicol. 2020 Feb;39(2):173-181. /[2]Wang Y, et al. Prucalopride might improve intestinal motility by promoting the regeneration of the enteric nervous system in diabetic rats. Int J Mol Med. 2022 Jul;50(1):87. /[3]Briejer MR, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001 Jun 29;423(1):71-83.
CAS Number: 179474-81-8
Molecular Weight: 367.87
Compound Purity: 99.81
Research Area: Neurological Disease; Cancer
Solubility: DMSO : ≥ 31 mg/mL/H2O : 50 mg/mL (ultrasonic)
Target: 5-HT Receptor;Apoptosis;Autophagy
Deutsch
English
